Matinas BioPharma to Present at the Barclays Global Healthcare Conference
March 01 2021 - 7:30AM
Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced
that Jerome D. Jabbour, Chief Executive Officer, has been invited
to present a Company overview at the Barclays Global Healthcare
Conference on Tuesday, March 9, 2021 at 4:45 p.m. ET. The Company
will also host investor meetings during the conference.
A live webcast of the Company’s presentation
will be available on the IR Calendar page of
the Investors section of the Company’s website
(www.matinasbiopharma.com). A webcast replay will be accessible for
90 days following the live presentation.
About Matinas BioPharma
Matinas BioPharma is a clinical-stage
biopharmaceutical company focused on developing next generation
therapeutics to advance standards of care for patients in areas of
significant unmet medical need. Company leadership has a deep
history and knowledge of drug development and is supported by a
world-class team of scientific advisors.
LYPDISO, the Company’s lead product candidate
for the treatment of cardiovascular and metabolic conditions, is a
prescription-only omega-3 fatty acid-based composition, comprised
primarily of EPA and DPA, under development for
hypertriglyceridemia.
In addition, Matinas is developing a portfolio
of products based upon its proprietary lipid nanocrystal (LNC) drug
delivery platform, which can solve complex challenges relating to
the safe and effective delivery of potent medicines, making them
orally bioavailable, less toxic, and targeted to cells and
tissues.
MAT2203 is an oral, encochleated formulation of
the well-known, but highly toxic, antifungal medicine amphotericin
B, primarily used to treat serious invasive fungal infections.
MAT2203 is currently in a Phase 2 open-label, sequential cohort
study (EnACT) in HIV-infected patients with cryptococcal
meningitis. EnACT is currently enrolling patients in its second
cohort, with the next DSMB evaluation of safety and efficacy data
anticipated to occur in the middle of 2021.
MAT2501 is an oral, encochleated formulation of
the broad-spectrum aminoglycoside antibiotic medicine amikacin,
primarily used to treat chronic and acute bacterial infections. The
Company has been awarded up to $3.75 million from the Cystic
Fibrosis Foundation (CFF) to support development of MAT2501 toward
an indication to treat nontuberculous mycobacterial (NTM) lung
disease, including infections in patients with cystic fibrosis
(CF).
Forward-Looking Statements
This release contains "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995, including those relating to the ENHANCE-IT
study, the Company’s strategic focus and the future development of
its product candidates, including MAT9001, the anticipated timing
of regulatory submissions, the anticipated timing of clinical
studies, the anticipated timing of regulatory interactions, the
Company’s ability to identify and pursue development and
partnership opportunities for its products or platform delivery
technology on favorable terms, if at all, and the ability to obtain
required regulatory approval and other statements that are
predictive in nature, that depend upon or refer to future events or
conditions. All statements other than statements of historical fact
are statements that could be forward-looking statements.
Forward-looking statements include words such as "expects,"
"anticipates," "intends," "plans," "could," "believes," "estimates"
and similar expressions. These statements involve known and unknown
risks, uncertainties and other factors which may cause actual
results to be materially different from any future results
expressed or implied by the forward-looking statements.
Forward-looking statements are subject to a number of risks and
uncertainties, including, but not limited to, our ability to obtain
additional capital to meet our liquidity needs on acceptable terms,
or at all, including the additional capital which will be necessary
to complete the clinical trials of our product candidates; our
ability to successfully complete research and further development
and commercialization of our product candidates; the uncertainties
inherent in clinical testing; the timing, cost and uncertainty of
obtaining regulatory approvals; our ability to protect the
Company’s intellectual property; the loss of any executive officers
or key personnel or consultants; competition; changes in the
regulatory landscape or the imposition of regulations that affect
the Company’s products; and the other factors listed under "Risk
Factors" in our filings with the SEC, including Forms 10-K, 10-Q
and 8-K. Investors are cautioned not to place undue reliance on
such forward-looking statements, which speak only as of the date of
this release. Except as may be required by law, the Company does
not undertake any obligation to release publicly any revisions to
such forward-looking statements to reflect events or circumstances
after the date hereof or to reflect the occurrence of unanticipated
events. Matinas BioPharma’s product candidates are all in a
development stage and are not available for sale or use.
Investor and Media
ContactsPeter
VozzoWestwicke/ICR443-213-0505peter.vozzo@westwicke.com
Ian CooneyDirector – Investor Relations &
Corporate DevelopmentMatinas Biopharma, Inc.(415)
722-4563icooney@matinasbiopharma.com
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From Sep 2023 to Sep 2024